Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s share price fell 1.9% during mid-day trading on Monday . The stock traded as low as $14.72 and last traded at $14.75, with a volume of 637,725 shares changing hands. The stock had previously closed at $15.03.

Several research firms have issued reports on LXRX. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Cowen and Company reaffirmed a “market perform” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, May 3rd. Wedbush increased their price objective on shares of Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, May 31st. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $16.00 price objective on shares of Lexicon Pharmaceuticals in a report on Thursday, May 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $18.50.

The company’s 50 day moving average price is $14.09 and its 200 day moving average price is $12.21. The firm’s market capitalization is $1.53 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.04. During the same period in the previous year, the business posted ($0.04) earnings per share. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $11.11 million. The business’s quarterly revenue was up 594.4% on a year-over-year basis. On average, equities analysts anticipate that Lexicon Pharmaceuticals Inc. will post ($1.55) EPS for the current fiscal year.

In related news, VP James F. Tessmer sold 6,000 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $78,000.00. Following the completion of the sale, the vice president now owns 21,946 shares of the company’s stock, valued at approximately $285,298. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Other hedge funds have bought and sold shares of the company. California State Teachers Retirement System increased its stake in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,372 shares during the period. ProShare Advisors LLC increased its stake in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 6,390 shares during the period. Nationwide Fund Advisors increased its stake in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 77,446 shares during the period. New York State Common Retirement Fund increased its stake in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 125,083 shares during the period. Finally, Eagle Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at about $8,426,000.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.